Sharyn Baker, PharmD, PhD

Sharyn D. Baker, PharmD, PhD

Associate Member, St. Jude Faculty
Director, Pharmacokinetics Shared Resource

Departments

Pharmaceutical Sciences

Contact Information

Sharyn Baker, PharmD, PhD
Pharmaceutical Sciences
MS 314, Room D1034
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: sharyn.baker@stjude.org
Phone: (901) 595-3089
FAX: (901) 595-3125

Education

BA - Pacific Lutheran University, Tacoma, Washington (1986)
PharmD - University of California at San Francisco (1991)
PhD - Erasmus University, Rotterdam, the Netherlands (2004)


Research Interests


Selected Publications

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick SJ, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, and Baker SD. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood 122:3607-15, 2013.

Xie C, Drenberg D, Edwards H, Chen W, Inaba H, Xu X, Buck S, Taub JW, Baker SD, Ge Y. Panobinosat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK2, and RAD51. PLoS One 8:e79106, 2013. (PMCID: PMC3823972)

Baker SD , Zimmerman EI, Wang Y-D, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen S, Enemark EJ, Rubnitz JE, Shurtleff S, Mullighan CG, Inaba H. Emergence of FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive AML. Clin Cancer Res 19:5758-68, 2013.

Navid F, Christensen R, Inaba H, Li L, Chen Z, Cai X, Regel J, Baker SD. Alternative Formulations of Sorafenib for Use in Children. Pediatr Blood Cancer 60:1642-6, 2013. (PMCID: PMC3800690)

Furmanski B, Hu S, Fujita K, Li L, Gibson AA, Janke L, Williams RT, Schuetz JD, Sparreboom A, Baker SD. Contribution of Abcc4-mediated gastric transport to the absorption and efficacy of dasatinib. Clin Cancer Res 19:4359-70, 2013. (PMCID: PMC3752901)

Broniscer A, Baker SD, Wetmore C, Panandiker AS, Huang J, Davidoff AM, Onar-Thomas A, Panetta JC, Chin TK, Merchant TE, Baker JN, Kaste SC, Gajjar A, Stewart CF. Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Clin Cancer Res 19:3050-8, 2013. (PMCID: PMC3685168)

Zimmerman EI, Hu S, Roberts JL, Li L, Sparreboom A, Baker, SD. Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide. Clinical Cancer Research 19:1458-66, 2013. (PMCID: PMC3602278)

Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, Davidoff AM, Spunt SL, Furman WL, McGregor LM, Hu S, Panetta JC, Turner D, Fofana D, Reddick WE, Leung W, Santana VM. Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors. Clinical Cancer Res 19:236-46, 2013. (PMCID:PMC3537913)

Zimmerman EI, Roberts JL, Li L, Finkelstein D, Gibson A, Chaudhry AS, Schuetz EG, Rubnitz JE, Inaba H, and Baker SD. Ontogeny and sorafenib metabolism. Clin Cancer Res. 18:5788-95, 2012. (PMCID:PMC3490489)

Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer 107:1100-6, 2012.

de Graan AJ, Lancaster C, Obaidat A, Hagenbuch B, Elens L, FribergL , de Bruijn P, Hu S, Gibson A, Bruun G, Corydon T, Mikkelsen T, Walker A, Du G, Loos W, van Schaik R, Baker SD, Mathijssen R, Sparreboom A. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 18: 4433-4440, 2012. (PMCID:PMC3464009)

Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, Bowman WP, Christensen R, Onciu M, Shurtleff SA, Pounds SB, Pui C-H, Ribero RC, Campana D, Baker SD. Phase I, Pharmacokinetic, and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination with Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. J Clin Oncol 29:3293-3300, 2011. (PMCID: PMC3158600)

Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, Yang S, Pounds S, Calabrese C, Rehg JE, Campana D, Rubnitz J, Baker SD. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 103:893-905, 2011.

Franke RM, Lancaster CS, Peer CJ, Gibson AA, Kosloske AM, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A. Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism. Clin Pharmacol Ther Mar 30, 2011.

Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, Sue L. Heatley SL, Holmfeldt L, Collins-Underwood JR, Ma J, Buetow KH, Pui C-H, Baker SD, Brindle PK, Downing JR. CREBBP mutations in relapsed acute lymphoblastic leukemia. Nature 471:235-9, 2011. (PMCID: PMC3076610)

Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, Campana D, Pui C-H, Downing JR, Rubnitz JE, Ribeiro RC. Identification of predictive markers of cytarabine response in acute myeloid leukemia by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 12:327-39, 2011. (PMCID: PMC3139433)

Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat 127:153-62, 2011. (PMCID: PMC3111459)

Smith BD, Jones RJ, Cho E, Kowalski J, Karp JE, Gore SD, Vala M, Meade B, Baker SD, Zhao M, Piantadosi S, Zhang Z, Blumenthal G, Warlick ED, Brodsky RA, Murgo A, Rudek MA, Matsui WH. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res 35:87-94, 2011. (PMCID: PMC3033102)

Pratz K, Cho E, Levis JM, Karp JE, Gore SD, McDevitt M, Stine A, Zhao M, Carducci MA, Wright JJ, Baker SD, Rudek MA, Smith BD. A pharmacodynamic study of sorafenib in patients with relapsed and refractory leukemias. Leukemia 24:1437-44, 2010. (PMCID: PMC2921005)

Li L, Zhao M, Navid F, Pratz K, Smith BD, Rudek MA, Baker SD. Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:3033-8, 2010. (PMCID: PMC2956857)

Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer. J Clin Oncol 28:4562-7, 2010. (PMCID: PMC2974340)

van Erp N, Baker SD, Zandvliet A, Ploeger B, Hollander M, Chen Z, Hartigh J, Konig-Quartel J, Guchelaar, HJ, Hans G. Increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol 67:695-703, 2011. (PMCID: PMC3043256)

Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs 29:1057-65, 2011. (PMCID: PMC3110647)

Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 27:4986-93, 2009. (PMCID: PMC2799055)

Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res 15:6241-9, 2009. (PMCID: PMC2845396)

Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 15:6062-9, 2009. (PMCID: PMC2774722)

Call SK, Kasow KA, Barfield R, Madden R, Leung W, Horwitz E, Woodard P, Panetta JC, Baker S, Handgretinger R, Rodman J, Hale GA. Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant 15:274-8, 2009.

Baker SD, Hu S. Pharmacokinetic considerations for new targeted therapies. Clin Pharmacol Ther 85:208-11, 2009. (PMCID: PMC2628961)

Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85:155-63, 2009. (PMCID: N/A)

Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower R. Phase I study of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, in adult patients with solid tumors. J Clin Oncol 26:5504-10, 2008.

Franke RM, Baker SD, Mathijssen RH, Schuetz E, Sparreboom A. Influence of Solute Carriers on the pharmacokinetics of CYP3A4 Probes. Clin Pharmacol Ther 84:704-9, 2008. (PMCID: N/A)

Minkin P, Zhao M, Chen Z, Ouwerkerk J, Gelderblom H, Baker SD. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry (LC/MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 874:84-8, 2008. (PMCID: PMC2612784)

Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Heather J, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo D. Pharmacodynamic-guided modified continuous reassessment method (mCRM) –based, dose finding study of rapamycin in adult patients with solid tumors. J Clin Oncol 26:4172-9, 2008. (PMCID: PMC 2654371)

Navid F, Christensen R, Minkin P, Stewart C, Furman WL, Baker SD. Stability of Sunitinib in Oral Suspension. Ann Pharmacother 42:962-6, 2008. (PMCID: N/A)

Hooker AC, ten Tije AJ, Carducci MA, Weber J, Garrett-Mayer, Gelderblom H, McGuire WP, Verweij J, Karlsson MO, Baker SD. Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements. Clin Pharmacol Ther 84:111-8, 2008. (PMCID: PMC3092481)

Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Priet R, Collins C, Fleisher M, Heller G, Baker SD, Scher HI. A Phase II Trial of Docetaxel with Rapid Androgen Cycling as a Treatment for Patients with Prostate Cancer. J Clin Oncol 26:2959-65, 2008. (PMCID: PMC3051836)

Hu S, Niu H, Minkin P, Orwick S, Shimada A, Inaba H, Dahl GVH, Rubnitz J, Baker SD. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther 7:1110-20, 2008. (PMCID: N/A)

Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD. Sparreboom A. Interaction of Imatinib with Human Organic Ion Carriers. Clin Cancer Res 14:3141-8, 2008. (PMCID: N/A)

Smith NF, Baker SD, Harris JW, Figg WD, Sparreboom A. Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. Br J Cancer 98:1630-2, 2008. (PMCID: PMC2391127)

Li J , Jameson MB, Baguley BC, Pili R, Baker SD. Population pharmacokinetic-pharmacodynamic (PK-PD) model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in cancer patients. Clin Cancer Res 14:2102-10, 2008. (PMCID: N/A)

Gregorc V, Hidalgo M, Spreafico A, Cusatis G, Ludovini V, Ingersoll RG, Marsh S, Steinberg SM, Viganò MG, Ghio D, Villa E, Sparreboom A, Baker SD. Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib. Clin Pharmacol Ther 83:477-84, 2008. (PMCID: N/A)

Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 61:423-33, 2008. (PMCID: N/A)

Jimeno A, Messersmith WA, Lee CK, Ma WW, Laheru D, Donehower RC, Baker SD, Hidalgo M. Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. Ann Oncol 19:374-9, 2008. (PMCID: N/A)

2000-2007 publications

Last update: December 2013